Citizens Maintains Market Outperform on Terns Pharma, Raises Price Target to $35

Benzinga · 11/26/2025 11:10
Citizens analyst Silvan Tuerkcan maintains Terns Pharma (NASDAQ:TERN) with a Market Outperform and raises the price target from $25 to $35.